Commercial aspects of vaccine development

Halliday, J. (2016). Commercial aspects of vaccine development. In Mariusz Skwarczynski (Ed.), Micro and nanotechnology in vaccine development (pp. 411-421) Oxford, United Kingdom: Elsevier. doi:10.1016/B978-0-323-39981-4.00022-1


Author Halliday, J.
Title of chapter Commercial aspects of vaccine development
Title of book Micro and nanotechnology in vaccine development
Place of Publication Oxford, United Kingdom
Publisher Elsevier
Publication Year 2016
Sub-type Research book chapter (original research)
DOI 10.1016/B978-0-323-39981-4.00022-1
Open Access Status Not yet assessed
Series Micro & nano technologies
ISBN 9780323400299
Editor Mariusz Skwarczynski
Chapter number 22
Start page 411
End page 421
Total pages 11
Total chapters 22
Collection year 2017
Language eng
Abstract/Summary The development of any therapeutic for human or animal use is a lengthy and highly regulated process. There are multiple factors that are important in assessing commercial attractiveness in the development of any new vaccine, and continual evaluation of these factors during the process is essential in developing new and improved vaccines. This chapter reviews the challenges associated with vaccine development and commercialization generally in the context of the various classes of micro- and nanotechnology vaccines and vaccine delivery devices that are in clinical development. The commercial challenges as well as potential advantages associated with the development of nanotechnology vaccines will be discussed.
Keyword Commercialization
Microtechnology
Nanotechnology
Vaccine
Q-Index Code B1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Book Chapter
Collection: HERDC Pre-Audit
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 03 Feb 2017, 16:02:56 EST by System User on behalf of Learning and Research Services (UQ Library)